Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB-GEN Study: Neuropharmagen in MDD
NCT02529462Phase 3Completed
- Sponsor
- AB-BIOTICS
- Start
- Jul 2014
- Primary completion
- Oct 2015
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial (2 arms), sponsored by AB-BIOTICS. Primary endpoint: Sustained response to treatment at 3 months. Started Jul 2014; status: completed.
Beyond the preview
Go deeper on NCT02529462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529462.